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Abstract 
Background: The impact of adjuvant radiotherapy (RT) on atypical meningioma (AM) underwent a gross total resec‑
tion (GTR) remains unclear, showing conflicting results from various studies. The objective of this study was to perform 
an updated meta‑analysis for observational studies to determine the effect of adjuvant RT after GTR on local recur‑
rence and survival outcomes compared to observation after GTR.
Methods: PubMed, Embase, and Web of Science were searched to identify comparative studies that reported out‑
comes of adjuvant RT versus observation for AM patients after GTR. Local recurrence rate, progression‑free survival 
(PFS), overall survival (OS), and toxicities related to RT were considered as outcomes of interest. Differences between 
two cohorts were estimated by calculating odds ratios (OR) for LR rate and hazard ratios (HR) for survival outcomes 
with 95% confidence intervals (CIs) for meta‑analysis, using R version 4.0.3 software. Included studies were appraised 
with the Risk of Bias Assessment tool for Non‑Randomized Studies. Outcome ratios were combined with the Mantel–
Haenszel method and the inverse variance‑weighted method, appropriately.
Results: Data from 30 studies involving 2904 patients (adjuvant RT: n = 737; observation: n = 2167) were eventually 
included. Significant reduction of local recurrence rate was seen in the adjuvant RT cohort compare to that in the 
observation cohort (OR 0.50; 95% CI 0.36–0.68; p < 0.0001). Pooled HRs of PFS at 1‑year, 3‑year, 5‑year, and > 5‑year 
revealed that adjuvant RT was superior to observation. There was no significant difference in OS between the two 
cohorts during any period. Most toxicities were tolerable with grade 1 or 2. There was no documented grade 5 
toxicity.
Conclusions: For AM patients who underwent GTR, evidence suggested that adjuvant RT could potentially decrease 
local recurrence and improve PFS better than observation.
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Introduction
Since the implementation of the 2007 World Health 
Organization (WHO) grading classification, the first 
to consider brain invasion as a diagnostic criterion of 
atypical meningioma (AM), the proportion of AM in 
newly diagnosed meningioma has increased from less 
than 10% to approximately 20–35% [1–5]. Traditionally, 
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maximal surgical resection has been considered as the 
most important factor for predicting the prognosis of 
AM. However, even a after gross total resection (GTR), 
recurrence can occur in a substantial portion of patients 
because of its unpredictable behavior and heterogene-
ity [6–8]. The recurrence of AM has been associated 
with significant morbidity and increased mortality. Thus, 
effort to reduce recurrence should be prioritized in the 
management of AM patients.
It is widely accepted that adjuvant radiotherapy (RT) 
can affect favorable prognosis of AM patients after a 
subtotal resection (STR). However, the impact of RT on 
AM patients after a GTR remains controversial. Several 
retrospective studies have investigated the effect of adju-
vant RT compared to observation after GTR, showing 
inconsistent results most likely due to a small sample size 
of each study, especially in the cohort that receives adju-
vant RT following GTR [6, 9–16]. Recently, two multi-
cohorts non-randomized phase II observational studies 
have reported a potential benefit of local control with 
adjuvant RT after GTR in AM patients [17, 18]. However, 
neither study was designed to directly compare adju-
vant RT versus observation in AM patients with GTR. 
Two randomized phase III trial, ROAM/EORTC-1308 
(Radiotherapy versus Observation following surgical 
resection of Atypical Meningioma/European Organiza-
tion for Research and Treatment of Cancer-1308) and 
NRG-BN003 (Observation Versus Irradiation for a Gross 
Totally Resected Grade II Meningioma) are currently 
underway to investigate whether adjuvant RT is superior 
to observation for reducing the recurrence of AM after 
GTR [19, 20]. Until results of these randomized trials are 
known, it is necessary to synthetically analyze outcomes 
of previously reported studies for deciding an optimal 
treatment strategy for AM patients after GTR.
The primary aim of the current study was to compare 
local recurrence and survival outcomes between adjuvant 
RT and observation cohorts of AM patients after GTR. 
To achieve this aim, we conducted an updated systematic 
review and meta-analysis for relevant clinical observa-
tional studies with a comparative design.
Materials and methods
Search strategy and study selection criteria
In accordance with the PRISMA (Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses) 
statement [21], we performed a meta-analysis of clini-
cal studies that investigated the effect of adjuvant RT 
after GTR on AM. A thorough search for eligible stud-
ies in electronic databases of PubMed, Embase, and 
Web of Science from inception to August 10th, 2020 
was conducted by two independent researchers (M.S.K 
and S.W.C). Search strategies utilized for each database 
are presented in Additional file  1: Table  S1. Search 
results were screened by scanning abstracts using the 
following exclusion criteria: case report, technical note, 
review, letter or conference abstract; duplicate study; 
single cohort study; article dedicated to adjuvant radio-
surgery (e.g., gamma knife surgery, cyberknife, stereo-
tactic linear accelerator-based radiosurgery), proton or 
carbon ion radiotherapy, or brachytherapy; and arti-
cle not about the population of interest (e.g., clear cell 
meningioma, chordoid meningioma). After all retrieved 
studies were reviewed, reference lists of reviews were 
also screened for qualifying studies. Only articles in 
English were considered since Morrison et al. reported 
no significant difference in pooled effects from the use 
of language restrictions in systematic review-based 
meta-analysis in medicine [22]. No limitation was set 
on the date of publication. Any discrepancies between 
the two reviewers (M.S.K and S.W.C) were resolved by 
discussion.
Inclusion criteria, data extraction, and quality assessment
The goal of the search was to find articles that met the 
following inclusion criteria: (1) articles that described 
two distinctive cohort groups of AM patients who 
received either GTR only (observation cohort) or adju-
vant RT after GTR (adjuvant RT cohort); and (2) arti-
cles that reported the outcome of local recurrence rate, 
progression-free survival (PFS), and/or overall survival 
(OS) for each cohort. Studies with a non-homogene-
ous design that reported outcomes for AM with STR 
or malignant meningioma were included if they sepa-
rately reported outcomes according to whether adju-
vant RT was performed or not after GTR for AM. We 
excluded articles that included patients with extracra-
nial AM, salvageable RT for recurrent AM after GTR, 
and neurofibromatosis.
The following data were extracted from selected stud-
ies: author of study, year of publication, study design, 
country that the study was conducted, period of research, 
version of adopted WHO classification, definition of 
GTR in each study, total number of each cohort, recur-
rence rate or number, PFS, OS, and any complication 
associated with adjuvant RT, if feasible. Toxicities of each 
study were reevaluated for grading using Common Ter-
minology Criteria for Adverse Events (CTCAE) version 
5.0.
The methodological quality for an individual article 
was assessed using the Risk of Bias Assessment tool for 
Non-Randomized Studies (RoBANS) [23]. Two authors 
(M.S.K and S.W.C) performed a quality appraisal of each 
study independently. A consensus was reached by discus-
sion for any discrepancies among reviewers.
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Statistical analyses
The primary outcome was direct comparisons of local 
recurrence rate, PFS, and OS in the adjuvant RT and 
the observation cohort after GTR for AM. For analy-
sis of local recurrence, numbers of recurred patients in 
the adjuvant RT and the observation cohort were iden-
tified. Odds ratios (OR) and 95% confidence intervals 
(CIs) were combined using the Mantel–Haenszel sta-
tistical method. Hazard ratios (HR) and 95% CIs were 
adopted as indicators of PFS and OS. HR and 95% CIs 
were extracted directly from included articles. For arti-
cles containing only Kaplan–Meier curves, survival data 
was extracted indirectly using Engauge Digitizer version 
12.1, and outcomes were then derived pursuant to meth-
ods proposed by Tierney et  al. [24] Pooled HR was cal-
culated using an inverse variance-weighted method. OR 
and HR < 1 denoted outcome that was greater in the adju-
vant RT cohort. Fixed-effects or random-effects models 
were used depending on the study nature and statistical 
heterogeneity of included studies in each analysis.
Heterogeneity between studies were assessed using 
the Cochrane Q test and the Higgins  I2 statics. If p value 
of the Cochrane Q was less than 0.1 or  I2 value was 
larger than 50%, the presence of significant heterogene-
ity among studies was considered and a random-effects 
model was used. Otherwise, a fixed-effects model was 
employed. The risk of publication bias was evaluated 
statistically by calculation of the p value (two-sided) 
for Egger’s linear regression test and Begg rank corre-
lation, and graphically by inspection of funnel plots. p 
values of > 0.05 in Egger’s test and Begg rank correlation 
test were considered as absence of significant publica-
tion bias. All statistical analyses were performed using 
R version 4.0.3 (R Foundation for Statistical Computing, 
Vienna, Austria, 2008) and the meta package [25].
Results
Literature search and study quality assessment
The initial search identified 815 studies in PubMed, 1317 
in Embase, and 506 in Web of Science (Fig. 1). A total of 
1162 duplicate studies and 1386 studies were excluded 
according to inclusion and exclusion criteria after review-
ing titles and abstracts. The remaining 90 studies were 
subsequently given a full-text review. Of them, 60 studies 
were excluded because available data were not extract-
able in studies with non-homogenous design (n = 26), 
lack of comparative study arm (n = 14), insufficient and 
indiscernible data (n = 17), patients with extracranial 
lesions (n = 1), incomplete trial (n = 1), and overlapping 
study population (n = 1). Finally, a total of 30 studies were 
included in our meta-analysis (Table 1). Among these 30 
studies included in the current meta-analysis, five had a 
homogenous study design, solely reporting the outcome 
of AM patients who underwent GTR. Twenty-five studies 
had a non-homogenous design, reporting about AM with 
STR (n = 22) or malignant meningioma (n = 3) as well 
as AM with GTR. All studies with a non-homogenous 
design contained extractable data for clearly defined out-
comes, explicitly comparing observation and adjuvant RT 
after GTR for AM. All included studies had a retrospec-
tive design involving 2904 patients: 2167 were treated 
with GTR alone and 737 received adjuvant RT after GTR. 
GTR was defined as Simpson grade I-III in 19 studies, 
grade I-II in five studies, and grade I in three studies. 
Three studies described GTR or TR without using the 
Simpson grade.
Qualitative assessment of selected studies is sum-
marized in Additional file  1: Table  S2. The risk of bias 
in the selection of participants was high in two studies 
that included AM patients located only in the skull base 
[26] and lateral ventricle [27]. Twenty-five studies with a 
non-homogenous design had a high risk of confounding 
bias because confounding variables were not considered 
between the adjuvant RT or the observation cohort after 
GTR [3, 7, 10, 12, 13, 15, 16, 26–42]. One study with a 
non-homogenous design that adjusted for major con-
founding variables using propensity score matching was 
considered to have a low risk of confounding bias [11]. 
One study with a homogenous study design had a high 
risk of confounding bias because of insufficient infor-
mation for confounding variables [43]. The risk of per-
formance bias due to an inadequate measurement of 
intervention was high in seven studies without a clear 
description of the definition of adjuvant RT [7, 11, 12, 
14, 15, 29, 44]. The detection bias was low in all included 
studies. The attrition bias was high in 11 studies with 
missing data because of restriction in follow-up duration 
or loss to follow-up for analyzing the outcome [3, 10, 30, 
35, 36, 39–43, 45]. The risk of reporting bias was high in 
five studies that did not report the recurrence number or 
the percentage of each cohort [26, 34, 37, 40, 41].
Local recurrence
Of 30 studies included in our meta-analysis, 25 studies 
consisting of 1232 patients in the observation cohort 
and 384 in the adjuvant RT cohort reported relevant 
data regarding local recurrence after GTR for AM. The 
crude local recurrence rate in the adjuvant RT cohort 
was 18.23% (70/384), which was statistically lower 
than that (24.68%, 304/1232) of the observation cohort 
(p = 0.009). Subsequent pooled analysis of these stud-
ies revealed that adjuvant RT reduced the risk of local 
recurrence (OR 0.50; 95% CI 0.36–0.68; p < 0.0001) 
(Fig.  2a). Included studies had no significant hetero-
geneity  (I2 = 25%;  Tau2 = 0.2446; p = 0.13). Cumulative 
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analysis according to the publication year of each 
study showed that the adjuvant RT cohort had a ben-
efit in controlling local recurrence over the observation 
cohort, showing statistical significance in recent years 
(Fig. 2b).
A subgroup analysis based on the WHO classifica-
tion applied in each study showed that the crude local 
recurrence rate in studies using the 2007 or 2016 WHO 
classification was 17.65% (30/170) in the adjuvant 
RT cohort, which was significantly better than that 
(31.14%, 147/472) in the observation cohort (p = 0.001). 
Pooled analysis of studies of this subgroup showed sig-
nificant advantage of adjuvant RT compared to obser-
vation in terms of local recurrence of AM patients 
after GTR (OR 0.45; 95% CI 0.29–0.72; p = 0.0007) 
(Fig. 3b). Included studies had no significant heteroge-
neity  (I2 = 0%;  Tau2 = 0; p = 0.50). In subgroup analysis 
of studies using the 1993 or 2000 WHO classification, 
there was no significant difference in crude local recur-
rence rate between the observation cohort (16.67%) 
and the adjuvant RT cohort (16.28%; p = 0.951). Pooled 
analysis of corresponding studies showed no significant 
difference in local recurrence between the adjuvant 
RT cohort and the observation cohort (OR 0.79; 95% 
CI 0.14–4.51; p = 0.7910) (Fig.  3a). A random-effect 
model was applied because of significant heterogeneity 
 (I2 = 67%;  Tau2 = 2.0826; p = 0.03) among studies in this 
subgroup.
Fig. 1 Flow diagram showing the selection of relevant studies
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Survival outcomes
PFS and OS were evaluated at each period of 1-year, 
3-year, 5-year, and > 5-year. Serially pooled HRs of PFS 
revealed that adjuvant RT was superior to observa-
tion after GTR for AM, showing sustained significance 
with a long-term follow-up (Fig. 4). Actuarial 1, 3, and 
5-year PFS rates were 93.4%, 84.7%, and 80.5%, respec-
tively, in the adjuvant RT cohort. These rates were 
88.8%, 77.8%, and 68.3%, respectively, in the obser-
vation cohort. However, pooled HR of OS showed no 
significant differences between the adjuvant RT cohort 
and the observation cohort after GTR for AM (Fig. 5). 
Actuarial 1, 3, and 5-year OSs rate were 96.8%, 90.6%, 
and 86.1%, respectively, in the adjuvant RT cohort. 
These rates were 96.1%, 91.6%, and 86.6%, respectively, 
in the observation cohort.
Toxicities of Radiation
Adverse events related to RT were reported in 13 stud-
ies. Information on radiotherapy and adverse events 
of each study based on CTCAE 5.0 are presented in 
Table  2. There was no documented event of Grade 5 
toxicity. Most toxicities were consistent with Grade 1 
or 2. Grade 3 and 4 toxicities were reported in 7 (2.1%) 
and 9 patients (2.7%), respectively.
Table 1 Baseline characteristics of included studies
R, retrospective; OS, observational study; WHO, World Health Organization; GTR, gross total resection; RT, radiotherapy; SEER, Surveillance, Epidemiology, and End 
Results; NR, not reported
References Country Design Study period WHO criteria Simpson grade No. of patients
Adjuvant RT Observation
Condra et al. [28] USA R, OS, 1 institution 1964–1992 1993 1,2,3 4 21
Aghi et al. [44] USA R, OS, 1 institution 1993–2004 NR 1 8 100
Jo et al. [29] Korea R, OS, 1 institution 1997–2008 2000 1 19 13
Yu et al. [43] China R, OS, 1 institution 2003–2008 NR 1,2,3 47 11
Komotar et al. [9] USA R, OS, 1 institution 1992–2011 1993 1,2 13 32
Lee et al. [30] USA R, OS, 1 institution 1999–2009 2007 1,2,3 17 54
Park et al. [10] Korea R, OS, 1 institution 1997–2011 2000/2007 1,2,3 17 38
Aizer et al. [11] USA R, OS, 1 institution 1997–2011 NR 1,2,3 18 50
Sun et al. [45] USA R, OS, 1 institution 1993–2012 2007 1,2,3 39 112
Yoon et al. [12] USA R, OS, 2 institutions 2000–2010 2000 1,2,3 7 102
Wang et al. [26] Taiwan R, OS, 1 institution 2001–2009 2007 GTR 3 11
Jenkinson et al. [7] UK R, OS, 3 institutions 2001–2010 2000/2007 1,2,3 32 81
Yip et al. [32] Taiwan R, OS, 1 institution 2005–2014 NR TR 7 16
Endo et al. [31] Japan R, OS, 1 institution 2000–2013 2007 1,2 11 19
Bagshaw et al. [13] USA R, OS, 1 institution 1991–2014 2007 1,2,3 12 40
Graffeo et al. [14] USA R, OS, 1 institution 1988–2011 2016 1,2,3 8 61
Dohm et al. [34] USA R, OS, 1 institution 1993–2014 2007 1,2,3 12 37
Alghamdi et al. [3] Canada R, OS, 1 institution 2003–2013 NR GTR 1 43
Cho et al. [33] Korea R, OS, 1 institution 2003–2014 2000/2007 1,2 13 16
Shakir et al. [36] Canada R, OS, 1 institution 1992–2013 2007 1,2,3 12 28
Chen et al. [15] USA R, OS, 1 institution 1993–2014 1993/2000/2007 1,2,3 10 104
Budohoski et al. [35] UK R, OS, 3 institutions 2007–2014 2016 1,2,3 35 108
Zeng et al. [40] China R, OS, SEER data 2008–2015 2007 1,2,3 194 533
Zhi et al. [41] USA R, OS, 1 institution 2000–2012 2000/2007 1,2,3 26 72
Wang et al. [39] USA R, OS, 1 institution 2009–2018 2016 1,2,3 71 142
Lee et al. [16] Korea R, OS, 1 institution 2000–2013 2007 1,2,3 20 24
Ros‑Sanjuan et al. [38] Spain R, OS, 1 institution 1994–2014 2016 1 5 5
Li et al. [37] China R, OS, 1 institution 2008–2015 NR 1,2 50 151
Lee et al. [42] USA R, OS, 1 institution 2000–2015 2000/2007 1,2,3 18 133
Jiang 2020 [27] China R, OS, 1 institution 2008–2016 2007 1,2 8 10
Page 6 of 14Chun et al. Radiat Oncol           (2021) 16:34 
Fig. 2 a Forest plot comparing the risk of local recurrence between the adjuvant RT cohort and the observation cohort. The risk of local recurrence 
is higher in the observation cohort. b Cumulative forest plot showing pooled OR of local recurrence according to the publication year. The first row 
shows the effect based on one study. The second row shows the cumulative effect based on two studies, and so on
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Publication bias
Publication bias results of included studies are shown in 
Table  3. All results of Egger’s test and Begg rank corre-
lation had p value > 0.5 with relatively symmetric funnel 
plots, indicating no substantial evidence for publication 
bias in the dataset.
Discussion
The current meta-analysis included 30 studies with 2167 
patients in the observation cohort and 737 patients in 
the adjuvant RT cohort. The local recurrence rate was 
lower in the adjuvant RT cohort than that in the obser-
vation cohort. However, in subgroup analysis, this result 
was proven to be true for studies using the 2007 or 2016 
WHO classification, but not for those adopting previous 
classifications. PFS was better in the adjuvant RT cohort 
than in the observation cohort regardless of the follow-
up term. However, OS did not differ significantly between 
the two cohorts.
The impact of adjuvant RT following GTR on AM 
patients compared to observation remains controver-
sial. Management strategies among physicians also vary 
in clinical practice due to conflicting results of previous 
individual studies [46]. A past meta-analysis has reported 
that postoperative RT may decrease the risk of tumor 
recurrence for AM patients after GTR [47]. However, it 
is controversial to determine the effectiveness of adjuvant 
RT compared to observation based on this single meta-
analysis. It included only 14 studies published by 2012 
with a relatively small number of total subjects (n = 757). 
Additionally, it included several studies with single-arm 
design which had an innate bias in assessing outcomes 
of relative values. Many studies have been reported since 
then. Outcomes of these studies should be considered 
for analyzing the benefit of adjuvant RT over observation 
following GTR for AM patients. We conducted an up-
to-date and systematic review and meta-analysis involv-
ing 2167 patients in the observation cohort and 737 in 
the adjuvant RT cohort. In the present meta-analysis, 
we found that adjuvant RT had a benefit of decreasing 
local recurrence rate (OR 0.50; p < 0.0001) compared to 
observation for AM patients after GTR. Furthermore, the 
pooled outcome of prolonged PFS (HR: 0.67; p = 0.0024) 
also showed a high statistical significance that individual 
studies failed to confirm due to their small sample sizes. 
Results of the current study can help us establish appro-
priate management strategy for AM patients following 
GTR in clinical practice.
In general, brain invasion had long been recognized as 
an adverse factor that is related to a higher risk of local 
recurrence [44, 45, 48–50]. To reflect this widespread 
conception, the 2007 WHO classification first considered 
Fig. 3 Forest plots comparing the risk of local recurrence between the adjuvant RT cohort and the observation cohort in subgroups using a 1993 
or 2000 WHO criteria and b 2007 or 2016 WHO criteria for included studies. The benefit of adjuvant RT in local recurrence is significantly higher in a 
subgroup using the 2007 or 2016 WHO criteria
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Fig. 4 Forest plots showing PFS at each period of 1‑year, 3‑year, 5‑year, and > 5‑year between the adjuvant RT cohort and the observation cohort. 
The advantage of PFS is observed in the adjuvant RT cohort, showing increasing significance with longer period
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brain invasion as a staging feature in the diagnosis of 
AM. In the 2016 WHO classification, brain invasion was 
eventually included as a criterion that was sufficient for 
diagnosing AM by itself [2]. In our subgroup analysis of 
studies using the 2007 or 2016 WHO classification, adju-
vant RT significantly reduced local recurrence (OR 0.45; 
p = 0.0007) with a low recurrence rate (17.65%) compare 
to observation (31.14%) for AM patients after GTR. This 
result implies the utility of adjuvant RT for AM patients 
after GTR, especially in the current era of the 2016 WHO 
classification when the diagnosis of AM is increasing. 
Unlike the subgroup analysis of studies using the 2007 or 
2016 WHO classification, the subgroup analysis of stud-
ies on patients with AM according to the 1993 or 2000 
WHO classification which did not include brain invasion 
as a diagnostic feature showed no significant difference 
Table 2 Toxicities of radiotherapy
CTCAE, Common Terminology Criteria for Adverse Events; RT, radiotherapy; 3D-CRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated 
radiotherapy; NR, not reported
*Patients no. such as AM with STR or malignant meningioma who underwent RT in studies with non-homogenous design
† Indicate mean value
Study No. of patients Radiation technology Radiation dose (Gy) Adverse events according 
to CTCAE grade (No. 
of patients)Median Range Per fx (no. of fx)
Aghi et al. [44] 8 NR 60.2† 59.4–61.2 1.5–1.8 Grade 4 radiation necrosis 
(n = 1)
Komotar et al. [9] 13 NR 59.4 NR 1.8–2.0 Grade 1–2 skin dermatitis, 
erythema, alopecia, fatigue, 
and headache (NR)
Park et al. [10] 17 + 10* Conventional RT/ 3D‑CRT 61.2 40.0–61.2 NR (30–35) Grade 1–2 fatigue, headache, 
nausea, dizziness, skin irrita‑
tion (NR)
Aizer et al. [11] 18 + 12* NR 60.0 55.8–64.0 NR Grade 4 radiation related 
glioblastoma (n = 1)
Sun et al. [45] 39 NR 53.8 46.0–60.0 1.7–2.0 Grade 1–2 radiation necrosis 
(n = 1)
Grade 4 radiation necrosis 
(n = 3)
Wang et al. [26] 3 + 9* NR NR 54.0–60.0 NR (27–30) Grade 1–2 headache, dizzi‑
ness, and skin irritation (NR)
Bagshaw et al. [13] 12 + 9* NR 54.0 45.0–59.4 NR Grade 1 fatigue, headache, 
and seizure (n = 4)
Grade 2 headache, dizziness, 
alopecia, and hearing and 
memory impairment (n = 4)
Grade 3 radiation necrosis 
(n = 2)
Grade 4 optic nerve disorder 
(n = 1)
Graffeo et al. [14] 8 NR 54.0 50.5–61.2 NR (28–30) Undetermined grade major 
morbidity (n = 1)
Dohm et al. [34] 12 + 51* 3D‑CRT 55.7 50.4–59.4 NR (28–35) Grade 4 seizure (n = 1)
Grade 3 radiation necrosis, 
cognitive disturbance, 
peripheral neuropathy, 
seizure, aphasia, and optic 
nerve disorders (n = 7)
Cho et al. [33] 13 + 21* Conventional RT NR 30.0–61.2 NR (30–35) Grade 1–2 fatigue, headache, 
nausea, dizziness, and skin 
irritation (NR)
Shakir et al. [36] 12 + 3* 3D‑CRT 54.0 52.2–59.4 1.8 Grade 1–2 headache, diz‑
ziness, and paresthesia 
(n = 8)
Lee et al. [16] 20 + 33* 3D‑CRT/IMRT 50.4/54.0 36.0–64.0/50.4–59.4 1.8–2.0 Grade 1 radiation necrosis 
(n = 2)
Ros‑Sanjuan et al. [38] 5 + 8* 3D‑CRT NR NR NR Undetermined grade radia‑
tion necrosis (n = 1)
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in local recurrence rate between adjuvant RT and obser-
vation cohorts. Results of current meta-analyses are 
emphatic about the need of integrative assessment of 
brain invasion for higher accuracy using multimodalities 
such as histopathological, operative, and image findings 
for establishing appropriate treatment for AM patients.
In the current meta-analysis, there was no statistical 
difference in pooled OS for any period between adju-
vant RT and observation cohorts, in line with results 
of included individual studies [39, 40]. Zeng et  al. have 
reported that the OS of AM patients who undergo GTR 
only is similar to that of patients who receive adjuvant 
RT after GTR or STR regardless of the extent of resec-
tion [40]. The extent of resection for AM can be an over-
whelmingly significant factor to improve the OS, enough 
to conceal the effect of adjuvant RT. The improvement of 
salvageable modalities for recurrent AM might have miti-
gated the difference of OS between two cohorts. Several 
studies have reported the benefit of survival extension 
through salvage therapy using ion radiotherapy, brachy-
therapy, and radiosurgery [51–53]. Despite the benefit of 
salvage therapy, aggressive upfront treatment after the 
first surgery for AM should be considered because of a 
low durability in local control of salvage therapy [51]. 
Furthermore, recurrent meningioma tends to be more 
aggressive than the original tumor, causing failure of sal-
vage therapy. It may offset the effect of adjuvant RT on 
OS of AM patients [28, 54, 55].
Neurotoxicity of adjuvant RT is a major cause that 
makes physicians hesitate to apply it for AM patients 
after GTR. The incidence of neurotoxicity varies, rang-
ing from 3.4% to 16.7% according to the location of the 
lesion, radiation dose, and radiation modality. However, 
advanced techniques for RT can lead to improvement 
in side effect profile and conventional fractionation RT 
can provide a far lower toxicity than hypofractiona-
tion RT or radiosurgery [56, 57]. Furthermore, most 
neurotoxicities are within tolerable levels using proper 
medical treatment [58]. In a phase II parallel observa-
tion study (EORTC 22,042–26,042), Weber et  al. have 
reported that the rate of late adverse effect of CTCAE 
grade 3 or more associated with adjuvant RT following 
GTR for AM is 14.3% (3/56) and that there is no toxic 
death (grade 5) [18]. In studies included in the current 
review, no death related to RT was reported and the 
occurrence of toxicities of grade 3 or more was 5.4% 
(18/336). Documented grade 4 toxicities included radi-
ation necrosis (n = 4), optic nerve disorder (n = 1), sei-
zure (n = 1), and radiation-related glioblastoma (n = 1). 
Although toxicities are usually mild, serious toxicity 
such as optic neuropathy and radiation-induced malig-
nancy should not be overlooked when considering 
adjuvant RT for AM patients after GTR. Therefore, it 
is imperative to carefully adjust the radiation dose and 
elaborate radiation technique to maximize the efficacy 
and minimize the toxicity in accordance with each 
patient. Additionally, although the toxicity of adju-
vant RT is at low-level, risk factors for recurrence in 
AM patients after GTR should be considered to avoid 
unnecessary toxicity and select proper candidates of 
adjuvant RT. Chen et  al. have reported that AM with 
MIB labelling index ≤ 7% have a very low risk (RR 0.06; 
95% CI 0.003–0.32; p = 0.0004) of recurrence after GTR 
[15]. Tumor size, secondary AM, and bone involvement 
have been reported in prior studies as risk factors of 
recurrence for AM patients after GTR [15, 39].
Several limitations exist in the present meta-anal-
ysis. First and foremost, it should be noted that all 
studies included were retrospective in nature, thus 
limiting implications of results. Another up-to-date 
Table 3 Summary of the publication bias in each meta-analysis
LR, local recurrence; PFS, progression-free survival; OS, overall survival; WHO, World Health Organization; SE, standard error; CIs, confidence intervals
Evaluation index Egger’s linear regression test Begg rank correlation
Intercept SE 95% CIs t value p value Tau z value p value
LR Overall  − 0.839 0.590  − 2.060 to 0.382 1.422 0.169  − 0.197 1.378 0.168
1993/2000 WHO criteria  − 1.911 7.191  − 32.852 to 29.031 0.266 0.815 0 0 1.000
2007/2016 WHO criteria  − 0.626 0.727  − 2.271 to 1.018 0.862 0.411  − 0.255 1.090 0.276
PFS 1‑year  − 0.080 0.546  − 1.371 to 1.211 0.147 0.888 0.139 0.521 0.602
3‑year  − 0.794 0.675  − 2.298 to 0.710 1.177 0.267  − 0.076 0.343 0.732
5‑year  − 0.791 0.815  − 2.607 to 1.024 0.971 0.354  − 0.106 0.480 0.631
 > 5‑year  − 1.094 0.662  − 2.570 to 0.382 1.652 0.130  − 0.409 1.851 0.064
OS 1‑year  − 0.519 1.114  − 5.314 to 4.276 0.466 0.687  − 0.167 0.340 0.734
3‑year  − 0.668 0.969  − 3.752 to 2.416 0.689 0.540  − 0.100 0.245 0.807
5‑year  − 0.737 0.588  − 2.371 to 0.896 1.253 0.279  − 0.400 1.127 0.260
 > 5‑year 0.026 0.338  − 0.913 to 0.965 0.077 0.942  − 0.267 0.751 0.452
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meta-analysis with the strongest level of evidence using 
two randomized phase II trials (ROAM/EORTC-1308 
and NRG-BN003) will be performed in the future after 
these trials are completed. Second, like all meta-analy-
ses, pooled results need to be interpreted acknowledg-
ing that local recurrence and survival outcomes can 
vary according to individual patients. Third, because of 
an insufficient number of studies with a homogenous 
design solely reporting outcomes of AM with GTR, we 
included studies with a non-homogenous design which 
might have caused confounding bias due to the fact that 
individual studies did not report confounding variables 
such as age, sex, location of the mass, or follow-up 
period according to the two cohorts of our interest. To 
reduce this risk of bias and provide an objective evalua-
tion, we conducted meta-analyses using only dataset of 
direct comparative studies. Moreover, heterogeneities 
of most pooled analyses were low and acceptable except 
in analysis about local recurrence of studies using the 
1993 or 2000 WHO criteria showing significant het-
erogeneity. Thus, the current meta-analyses about 
local recurrence and survival outcome have signifi-
cant implications about the effect of adjuvant RT after 
GTR on AM patients compared to observation after 
GTR. Finally, the systematic review of toxicity should 
be interpreted with caution because it included adverse 
effects occurring in patient populations not strictly 
confined to those with AM and received adjuvant RT 
after GTR.
Conclusions
Currently, available evidence supports the finding that 
adjuvant RT confers significant benefits for local con-
trol and PFS compared to observation in AM patients 
after GTR. However, adjuvant RT should be carefully 
considered to avoid unforeseen complications related 
to RT. It should be performed for AM patients with a 
high risk of recurrence after GTR. Randomized con-
trolled trials are necessary to provide further evidence 
for our results and assess which AM patients could 
have the greatest clinical benefit and the lowest toxicity 
of adjuvant RT following GTR.
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